Mediolanum International Funds Ltd Raises Stock Holdings in STERIS plc $STE

Mediolanum International Funds Ltd lifted its holdings in shares of STERIS plc (NYSE:STE) by 9.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,327 shares of the medical equipment provider’s stock after acquiring an additional 5,156 shares during the period. Mediolanum International Funds Ltd owned 0.06% of STERIS worth $14,883,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Orbis Allan Gray Ltd purchased a new stake in shares of STERIS in the first quarter valued at about $349,950,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in STERIS by 55.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider’s stock worth $344,617,000 after acquiring an additional 540,999 shares during the period. Nuveen LLC acquired a new position in STERIS in the 1st quarter valued at $65,435,000. Vanguard Group Inc. increased its stake in STERIS by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after buying an additional 205,276 shares during the period. Finally, Generation Investment Management LLP raised its position in STERIS by 5.4% during the 1st quarter. Generation Investment Management LLP now owns 3,354,545 shares of the medical equipment provider’s stock worth $760,308,000 after buying an additional 170,392 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the sale, the vice president owned 5,695 shares in the company, valued at approximately $1,466,747.25. This represents a 46.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel A. Carestio sold 159 shares of the business’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the transaction, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 20,195 shares of company stock worth $5,312,571 over the last ninety days. 1.07% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

STE has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Finally, Morgan Stanley increased their target price on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Stock Up 2.5%

STE opened at $263.34 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The company has a market cap of $25.85 billion, a price-to-earnings ratio of 40.33 and a beta of 1.02. STERIS plc has a one year low of $200.98 and a one year high of $268.30. The business’s fifty day moving average is $246.90 and its two-hundred day moving average is $241.41.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s dividend payout ratio is 36.21%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.